CLINICAL_TRIALS ClinicalTrials.gov record update

Combined Phase I/II Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00130936
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:00.508864+00:00
Published At: 2016-02-15T00:00:00+00:00
Record Updated At: 2016-02-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Gastric Cancer", "Esophageal Cancer", "Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-02-15"
protocolSection.identificationModule.nctId: "NCT00130936"
protocolSection.identificationModule.officialTitle: "Combined Phase I/II Study of Epirubicin (Pharmorubicin\u00ae), Carboplatin (Paraplatin\u00ae) and Capecitabine (Xeloda\u00ae) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.